You are here

Alexion

Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

Pharma Voice

Thu, 12/12/24 - 11:33 am

Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech

Pharma Voice

Tue, 11/5/24 - 10:02 am

clinical trials

AZ's Alexion inks $125M deal to resolve investor lawsuit over Soliris sales tactics

Fierce Pharma

Thu, 09/14/23 - 11:00 pm

EHA 2023 – Astrazeneca keeps up its complement defense

EP Vantage

Fri, 06/9/23 - 10:01 am

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

Fierce Biotech

Fri, 12/16/22 - 10:47 am

AstraZeneca pays 666% premium to buy genomic medicine biotech

Fierce Biotech

Mon, 10/3/22 - 10:26 am

LogicBio Therapeutics

genomic medicine

AstraZeneca's Alexion bet continues to pay off as danicopan improves hemoglobin levels in phase 3

Fierce Biotech

Mon, 09/19/22 - 09:25 am

paroxysmal nocturnal hemoglobinuria

Data backs AZ’s Wilson disease drug, but with a question mark

Pharmaforum

Fri, 06/24/22 - 10:26 am

AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven

Fierce Biotech

Mon, 04/18/22 - 10:48 am

AstraZeneca and Neurimmune close agreement to develop monoclonal antibody, NI006

Biopharma Reporter

Tue, 03/1/22 - 10:23 am

monoclonal antibodies

transthyretin amyloid cardiomyopathy

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Endpoints

Sun, 02/20/22 - 11:48 am

AstraZeneca and Neurimmune to develop investigational human monoclonal antibody NI006

Biopharma Reporter

Mon, 01/10/22 - 11:43 am

AstraZeneca blocks investor group's $7.6B buyout of rare disease specialist Sobi: report

Fierce Pharma

Fri, 12/3/21 - 10:45 am

AstraZeneca’s Alexion concludes Caelum acquisition for $500m

Pharmaceutical Business Review

Thu, 10/7/21 - 11:22 am

Caelum Biosciences

AstraZeneca lays out $360M for 'next-gen' manufacturing plant in Dublin

Fierce Pharma

Tue, 09/21/21 - 10:50 pm

drug manufacturing

After Ultomiris stumble, Alexion delivers a rare disease win for AZ

Pharmaforum

Thu, 08/26/21 - 11:09 am

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Fierce Pharma

Sun, 07/25/21 - 11:44 am

myasthenia gravis

AstraZeneca heralds new chapter as Alexion acquisition completed

Biopharma Reporter

Wed, 07/21/21 - 08:46 pm

Biopharma throws grease on the deal wheels

EP Vantage

Wed, 07/21/21 - 10:52 am

Prevail Therapeutics

Alexion's new blockbuster Ultomiris keeps gaining steam as $39B AstraZeneca deal looms

Fierce Pharma

Wed, 07/21/21 - 12:01 am

Pages